Zaher I. Chakhachiro, Rima M. Saliba, Grace-Julia Okoroji, Martin Korbling, Amin M. Alousi, Oran Betul, Paolo Anderlini, Stefan O. Ciurea, Uday Popat, Richard Champlin, Barry I. Samuels, L. Jeffrey Medeiros, Carlos Bueso-Ramos and Issa F. Khouri Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission Cancer 119
Article first published online: 17 JUN 2013 | DOI: 10.1002/cncr.28219
An elevated Ki-67 level of ≥ 30% is the most important determinant of disease recurrence in patients with mantle cell lymphoma who are receiving an autologous stem cell transplantation during their first remission. An alternative strategy is needed for these patients. Previous exposure to cytarabine was found to have no impact on either the recurrence or survival rate.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.